Hepatitis B Topics HBV Treatment
Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults
- Details
- Category: HBV Treatment
- Published on Thursday, 30 August 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) this week announced that product label information for tenofovir (Viread) has been revised to include further information about treatment of chronic hepatitis B in teenagers and 240-week data for adult patients. 
EASL Publishes Revised Clinical Practice Guidelines for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 17 July 2012 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) recently revised its clinical practice guidelines for the management of patients with chronic hepatitis B virus (HBV) infection. The new recommendations were announced at the International Liver Congress in April in Barcelona and published in the July 2012 Journal of Hepatology. 
EASL: Having Only Wild-type Hepatitis B Virus Predicts Response to Interferon
- Details
- Category: HBV Treatment
- Published on Friday, 04 May 2012 00:00
- Written by Liz Highleyman
Chronic hepatitis B patients who do not have 2 common HBV mutations are more likely to achieve undetectable viral load and HBsAg loss when treated with pegylated interferon, according to study findings presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
EASL: Telbivudine Effective for Hepatitis B Patients Selected with Roadmap
- Details
- Category: HBV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Telbivudine (Tyzeka) is an effective treatment for chronic hepatitis B with minimal emergence of drug resistance when using the "Roadmap" algorithm for selecting appropriate patients and deciding when to add other agents, according to a trio of studies presented at the 47th International Liver Congress (EASL 2012) last month in Barcelona.
Complete Coverage of the 2012 International Liver Congress
- Details
- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.
HIVandHepatitis.com EASL 2012 conference section
More Articles...
- EASL: Entecavir (Baraclude) Prevents Hepatitis B Recurrence after Liver Transplant
- EASL: Entecavir plus Tenofovir for Hepatitis B Patients with Prior Treatment Failure
- EASL International Liver Congress Starts This Week in Barcelona
- Do Not Use Telbivudine (Tyzeka) with Pegasys for Hepatitis B, FDA Warns
Web Design and Development by